Prof Frank Griesinger, medical oncologist at Pius Hospital, Oldenburg, Germany presents real-world data and outcomes in the US and Germany after first-line treatment with osimertinib in patients with EGFRm advanced NSCLC.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok